ATOS — Atossa Therapeutics Share Price
0.000.00%
Last trade - 00:00- $149.65m
- $65.69m
- 43
- 27
- 80
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.67 | ||
| Price to Tang. Book | 1.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.94% | ||
| Return on Equity | -30.01% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Directors
- Steven Quay CHM (70)
- Kyle Guse CFO (57)
- Shu-Chih Chen DRC (59)
- Stephen Galli IND (74)
- H. Lawrence Remmel IND (69)
- Richard Steinhart IND (64)
- Gregory Weaver IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- April 30th, 2009
- Public Since
- November 8th, 2012
- No. of Shareholders
- 41
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 125,757,416
- Address
- 107 Spring St, SEATTLE, 98104-1005
- Web
- https://atossatherapeutics.com/
- Phone
- +1 2065880256
- Auditors
- Ernst & Young LLP
Upcoming Events for ATOS
Q2 2024 Atossa Therapeutics Inc Earnings Release
Q3 2024 Atossa Therapeutics Inc Earnings Release
Similar to ATOS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Atossa Therapeutics share price?
As of Today at 19:26 UTC, shares in Atossa Therapeutics are trading at $1.13. This share price information is delayed by 15 minutes.
How has the Atossa Therapeutics share price performed this year?
Shares in Atossa Therapeutics last closed at $1.13 and the price had moved by +24.04% over the past 365 days. In terms of relative price strength the Atossa Therapeutics share price has underperformed the S&P500 Index by -1.3% over the past year.
What are the analyst and broker recommendations for Atossa Therapeutics?
The overall consensus recommendation for Atossa Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Atossa Therapeutics dividend yield?
Atossa Therapeutics does not currently pay a dividend.
Does Atossa Therapeutics pay a dividend?
Atossa Therapeutics does not currently pay a dividend.
When does Atossa Therapeutics next pay dividends?
Atossa Therapeutics does not currently pay a dividend.
How do I buy Atossa Therapeutics shares?
To buy shares in Atossa Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atossa Therapeutics?
As of the previous close price of $1.13, shares in Atossa Therapeutics had a market capitalisation of $142.11m.
Where are Atossa Therapeutics shares listed?
Here are the trading details for Atossa Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATOS
What kind of share is Atossa Therapeutics?
Based on an overall assessment of its quality, value and momentum Atossa Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atossa Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Atossa Therapeutics is $5.42. That is 379.65% above the last closing price of $1.13.
Analysts covering Atossa Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
What is the trend in the Atossa Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atossa Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +26.62%.
As of the last closing price of $1.13, shares in Atossa Therapeutics were trading +6.5% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atossa Therapeutics PE Ratio?
The Atossa Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atossa Therapeutics?
Atossa Therapeutics' management team is headed by:
- Steven Quay - CHM
- Kyle Guse - CFO
- Shu-Chih Chen - DRC
- Stephen Galli - IND
- H. Lawrence Remmel - IND
- Richard Steinhart - IND
- Gregory Weaver - IND